Kornimate/medical-research-clean huggingface dataset:
medical consortium for screening upper gastrointestinal cancers with magnetically controlled capsule gastroscopy

Conditions: Capsule Endoscopy; Cancer of Stomach; Cancer of Esophagus; Health Policy

Summary: the aim of our study was to demonstrate the efficacy and feasibility of the medical consortium for screening upper gastrointestinal cancers with magnetically controlled capsule gastroscopy.

in this study, the investigators designed a propective cohort study to evaluate the the efficacy and feasibility of medical consortium for screening upper gastrointestinal cancers (mcsc) with magnetically controlled capsule gastroscopy (mccg).

Eligibility criteria:
inclusion criteria: * asymptomatic subjects undergong magnetically controlled capsule gastroscopy for health checkup in medical consotium; * subjects able to give informed consent exclusion criteria: * suspected or known intestinal stenosis, obstruction, or fistula; * inoperability of refusal to accept any abdominal surgery; * dysphagia or gastric paralysis; * previous history of gastrointestinal disease; * with pacemaker, implanted-cardiac defibrillator or other implanted electromedical devices; * need for standard magnetic resonance imaging examination within seven days after swallowing the mccg, unless the capsule is confirmed to have been excreted; * other factors that are not suitable for inclusion evaluated by medical stuff
sedentary behavior in overweight women

Conditions: Sedentary Behavior; Overweight

Summary: objective activity data will be collected using accelerometry for a minimum of seven days on 38 adult, female, women recruited from the metabolic clinic at the university of mississippi medical center. following objective measurement of activity, participants will complete self-report and objective activity data, as well as the relationship between sedentary activities and food cravings will be examined. it is hypothesized that minutes of sedentary behavior, especially time spent in television viewing, will be significantly correlated with total and specific food cravings.


Eligibility criteria:
inclusion criteria: caucasian or african american women between the ages of 18 and 65 exclusion criteria: males and women who are younger than 18 and older than 65

Keywords: female
spic frequency after surgical treatment of peri-implantitis

Conditions: Peri-Implantitis

Summary: the leading hypothesis behind this study is that a 3-month frequency of supportive peri-implant care (spic) recalls after surgical therapy of implants affected by severe peri-implantitis yields better results when compared to a 6-month frequency. thus, the primary aim of this randomized clinical trial is to compare 2 different frequencies of spic recalls (3 and 6 months) after surgical treatment of severe peri-implantitis in terms of treatment success (absence of implant loss, probing pocket depth (ppd) ≤ 5 mm at all aspects, bleeding on deep probing ≤1 site/implant, no suppuration at all aspects, bone loss \<0.5 mm) at early follow-up (1-year) and implant survival at the 5-year examination. secondarily, this randomized clinical trial aims to assess the effects of the 2 different frequencies over clinical attachment levels around remaining teeth.


Eligibility criteria:
any patient aged 18 years or more, who has at least one implant affected by severe peri-implantitis, and able to sign an informed consent form will be potentially eligible for this trial. severe peri-implantitis will be defined as the presence of a peri-implant probing pocket depth \[ppd\] ≥ 6 mm in at least 1 site of the implant, bleeding and/or suppuration on deep probing \[dbop and/or dsop, respectively\] and radiographically documented marginal bone loss \> 3 mm (carcuac et al. 2016; romandini et al. 2022) on implants in function by at least 12-months. in the absence of baseline radiographs, implants had to present a bone level \>3 mm (romandini et al. 2021b). patients fulfilling the above-mentioned inclusion criteria will not be included in the study if they appear to be unable to attend the study-related procedures (including the long-term follow-up visits) or if one or more of the following systemic or local exclusion criteria are detected during the enrolment phase. systemic primary exclusion criteria: * systemic diseases (e.g. uncontrolled diabetes mellitus) or chronic use of medications (e.g. corticosteroids, bisphosphonates) likely to influence the outcome of therapy or which contraindicates the study procedures; * smoking \>10 cigarettes; * pregnant or nursing women. local primary exclusion criteria: * history of peri-implantitis treatment on the eligible implants in the previous 6 months; * hopeless implants (\>80% of bone loss/level). a secondary inclusion criterion will be applied 1-month after surgery: - absence of peri-implant abscess on the implants to be included.
evaluation of two type iii gbs polysaccharide-tetanus toxoid conjugate vaccines

Conditions: Bacterial Infections; Group B Streptococcus

Summary: the purpose of this study is to test the safety and favorable immune response to an anti-streptococcal vaccine (a vaccine that treats a common bacterial infection) in healthy non-pregnant women. group b streptococcus (gbs) continues to be the single most frequent cause of life-threatening bacterial infection during the first 2 months of life. further, gbs pregnancy-related morbidity afflicts more than 50,000 women annually in the us. therefore, active immunization of women is an appealing strategy for the prevention of gbs disease in pregnant women and their infants during the first 3 months of infant life.

in this study 65 healthy, non-pregnant women will receive a single dose of one of two anti-streptococcal vaccinations. both types of vaccinations are given in upper arm by injection into the muscle. to assess the vaccine effectiveness, patients have blood drawn and examined at weeks 4, 8 and 26, post-vaccination.

Eligibility criteria:
this information currently is not available.

Keywords: clinical evaluation
hemiarthroplasty or internal fixation for displaced femoral neck fractures - 5 years follow up

Conditions: Femoral Neck Fractures

Summary: an estimated 1.6 million patients sustain a hip fracture every year, about half of these are intracapsular femoral neck fractures. a femoral neck fracture is a life changing event for any patient, and the risk of disability, increased dependence and death is substantial. the main treatment options for displaced femoral neck fractures are internal fixation and arthroplasty. it is established that there are more complications and reoperations after internal fixation, and better short term clinical results with arthroplasty, but knowledge about long term results is lacking.

patients were included from 2002-2004. two years follow up was finished by 2006. patients with displaced intracapsular femoral neck fractures were included and randomized by means of closed numbered envelopes to operation groups: 1. two parallel screws (olmed). 2. hemiarthroplasty with charnley/ hastings prosthesis. a priori one would expect that there would be less morbidity and mortality with the less extensive and quicker operation with parallel screw and that a faster and better rehabilitation would be achieved with hemiarthroplasty.

Eligibility criteria:
inclusion criteria: * displaced femoral neck fracture * age 60 or above * able to walk (any aids allowed) exclusion criteria: * anesthesiologically unfit for arthroplasty surgery * previous symptomatic hip pathology (i.e. arthritis) * pathological fracture * delay of more than 96 hours from injury to treatment * not living in hospital area

Keywords: displaced femoral neck fractures treatment function pain quality of life complications reoperations internal fixation hemiarthroplasty activities of daily living
patients' perspectives about a pain education video

Conditions: Pain

Summary: the overall goal of this single session semi-structured interview project is to explore the validation and contradiction of the preexisting pain beliefs in patients with chronic pain. aim 1: after patients watch an educational video, explore occurrences of perceived validation and contradiction and the impact of validation and contradiction on pain beliefs, emotion, and pain. aim 2: obtain patients' recommendations for improving the educational value of the video.

the long-term goal is to reduce disability in patients with chronic pain by improving communication about pain among patients, caregivers, and health care providers (hcps). the proposed study addresses the long-term goal by conducting a project that investigates the validation and contradiction of patients' preexisting pain beliefs during pain education. completion of the proposed project will advance the literature on validation and contradiction in patients with chronic pain by (1) focusing on a pain education resource instead of dyadic communication, (2) modifying a measure of validation and contradiction for relevance to an education resource, (3) exploring erroneous perceptions of validation and contradiction, (4) examining the impact of validation and contradiction on pain beliefs, and (5) obtaining patients' recommendations for a popular pain education film. the information gained will be used to improve pain education resources to increase their beneficial effects on pain and disability.

Eligibility criteria:
inclusion criteria: * 18 years old or older; * new patient of the cpmc; * living independently; and * self-reported recurrent or persistent pain on most days of the last year. exclusion criteria: * previously viewed the pain education video used in this project; * insufficient hearing to communicate with an interviewer; and * an inability to complete the session within the time allowable.
mineralocorticoid receptor antagonists in end stage renal disease

Conditions: End Stage Renal Disease / Hemodialysis

Summary: end stage renal disease (esrd) patients exhibit an extraordinarily high annual mortality. cardiovascular (cv) causes account for almost half of all-cause mortality. increased left ventricular mass (lvm) is a common finding in esrd patients on dialysis and is an independent predictor of survival. yet, to date there is no established medical treatment to reduce cv morbidity and mortality in esrd patients on hemodialysis. blockade of aldosterone action by means of mineralocorticoid receptor antagonists (mra) provides cardioprotection and improves outcome in heart failure patients. furthermore, the mra spironolactone has recently been shown to reduce lvm in patients with mild-to-moderate chronic kidney disease (ckd). the investigators here hypothesize that spironolactone treatment is cardioprotective by reducing lvm in esrd patients on dialysis.


Eligibility criteria:
inclusion criteria: * age \>18 years * hemodialysis treatment for at least 3 months * at least 3 dialysis sessions per week * written informed consent exclusion criteria: * contraindications for cardiac magnet resonance imaging (cmr) * mineralocorticoid receptor antagonist treatment within the last 6 months * estimated life expectancy \< 12 months as judged by the nephrologist * history of hyperkalemia, defined as pre-dialysis potassium \> 6.5 mmol/l occurring ≥ 3 times within the last 3 months prior to enrolment. * high risk to develop hyperkalemia defined as pre-dialysis potassium \> 6.0 mmol/l * hypotension (systolic blood pressure \< 100 mmhg) * planned kidney transplantation (living donor) within the prospected study duration * any acute illness within the last 4 weeks precluding a study participation as judged by the nephrologist * non-amenorrheic women with child bearing potential without reliable contraception, pregnancy/lactation * allergy/hypersensitivity to spironolactone * non-compliance suspected or demonstrated

Keywords: end stage renal disease hemodialysis spironolactone left ventricular hypertrophy
the penumbra liberty trial: safety and effectiveness in the treatment of wide-neck intracranial aneurysms

Conditions: Wide-neck, Saccular Intracranial Aneurysms

Summary: to assess the safety and effectiveness of the penumbra liberty stent system as adjunctive treatment to embolic coils for wide-neck, saccular, intracranial aneurysms in the internal carotid artery (ica). the liberty stent system is an implantable device comprised of a stent and delivery system designed as an adjunct to embolic coils in the treatment of wide-neck, saccular, intracranial aneurysms. it has three components: an implant, an introducer sheath and a delivery wire assembly. the implant component is made of superelastic and biocompatible nitinol tubular material. patients presenting with wide-neck, saccular, intracranial aneurysms in the internal carotid artery (ica) from the cavernous segment to the carotid terminus (including the paraclinoid, ophthalmic, hypophyseal and posterior communicating segments) will receive stent assisted coiling by the penumbra liberty stent with any approved embolic coils currently on the market. wide-neck aneurysms are defined by a neck ≥4mm or a dome-to-neck ratio \<2. each patient will be followed and assessed for 2, 6 and 12 months after enrollment.


Eligibility criteria:
inclusion criteria: * at least 18 years old * a wide-neck intracranial saccular aneurysm with a neck ≥ 4mm or a dome to neck ratio \<2 in the ica from the cavernous segment to the carotid terminus (including the paraclinoid, ophthalmic, hypophyseal and posterior communicating segments) * life expectancy \> 12 months * signed informed consent exclusion criteria: * females who are pregnant or intend to become pregnant during the study. (females of child-bearing potential must have a urinary pregnancy test within 7 days of enrollment) * extradural aneurysms * known multiple untreated cerebral aneurysms at study entry * recent history of subarachnoid hemorrhage, intracranial hemorrhage, or major surgery within one month of enrollment * admission platelet \ 3.0 * contraindication to angiography such as elevated creatinine or known allergy to angiographic contrast * contraindication to ct and/or mri scans * known allergy to the metal component of the penumbra liberty stent system * evidence of active infection (wbc \>10x109 /l) * any medical conditions that will not allow the necessary follow-up for this study (e.g., pre-existing neurological or psychiatric diseases) * current substance-abuse /illicit drug use * angiographic evidence of an arterial stenosis proximal to the target lesion that could prevent device deployment * contraindications to study medications (heparin, aspirin, clopidogrel, and radiographic contrasts)

Keywords: wide-neck saccular intracranial aneurysms ica stent assisted coiling liberty stent
metabolic effects of switching kaletra to boosted reyataz

Conditions: HIV Infections

Summary: to study the effects of switching from kaletra to boosted reyataz on glucose, lipids and fat in hiv-infected patients.

the primary objective of this study is to determine tissue specific glucose trafficking in patients before and after switching from a regimen containing lopinavir/ritonavir (lpv/r) to one containing atazanavir/ritonavir (atv/r). secondary outcome measures of interest will include insulin sensitivity determined by clamp testing, and lipid metabolism and hepatic glucose production assessed using stable isotope techniques. we hypothesize that switching protease inhibitor (pi) to atv/r from lpv/r will result in direct increases in glucose uptake in muscle and visceral adipose tissue in association with improvements in overall whole body insulin sensitivity compared to remaining on lpv/r. we will complete a prospective randomized trial of human immunodeficiency virus (hiv) infected patients who have been on a stable antiretroviral (arv) regimen containing lpv/r for at least 6 months and who will be randomized to either switch to a regimen containing atv/r or remain on lpv/r for 6 months. each subject will complete positron emission tomography (pet) 18-fluorodeoxyglucose (fdg) imaging during a hyperinsulinemic clamp study at baseline and 6 months after randomization.

Eligibility criteria:
inclusion criteria: 1. previously diagnosed hiv infection 2. age between 18-65 years 3. stable antiviral regimen containing at least 2 nucleoside reverse transcriptase inhibitors (nrti's) and lpv/r for ³ 6 mos 4. cd4 count \> 400 cell/mm3 5. metabolic complication as indicated by one or more of hyperinsulinemia (fasting insulin \>= 15 miu/ml), hypercholesteremia (fasting total cholesterol \>= 200 mg/dl), hypertriglyceridemia (fasting triglycerides \>= 150 mg/dl), or treatment with a lipid lowering medication. exclusion criteria: 1. hemoglobin \< 11.0 g/dl 2. history of diabetes mellitus 3. currently on medication for diabetes 4. therapy with glucocorticoid, growth hormone or other anabolic agents currently or within the past 3 months 5. current substance abuse, including alcohol, cocaine and/or heroin 6. any contraindication to atv/r or known allergy to atv 7. concurrent therapy with: bepridil; cisapride; ergot derivatives (dihydroergotamine, ergonovine, ergotamine, methylergonovine); indinavir; irinotecan; lovastatin; midazolam; pimozide; proton pump inhibitors (esomeprazole, lansoprazole, omeprazole); rifampin; simvastatin; st john's wort; or triazolam 8. new or serious opportunistic infection in the past 3 months 9. pregnancy

Keywords: hiv kaletra reyataz insulin sensitivity lipids body composition receiving kaletra treatment experienced
the effect of resistance training on muscle strength and nutritional status in patients with liver cirrhosis

Conditions: Liver Cirrhosis

Summary: the purpose is to investigate the effect of strength training on muscle strength, muscle mass and nutritional status in patients with liver cirrhosis to clarify possible metabolic and inflammatory changes during this intervention. in addition the investigator examine if the intervention is associated with fewer hospital readmission and an improved quality of life.


Eligibility criteria:
inclusion criteria: * cirrhosis, child pugh score a and b exclusion criteria: * cirrhosis, child-pugh score c at inclusion * neurological and/or psychiatric disorder * pregnancy, breastfeeding * patients with malignancy * patients with hepatic encephalopathy at inclusion * patients with atypical diets, such as vegans

Keywords: malnutrition muscle mass nutrition
enb-guided ablation therapy combined with vats in the treatment of mplc

Conditions: Lung Cancer

Summary: the study is designed as a prospective trial whose purpose is to evaluate the effectiveness and safety of enb-guided ablation therapy combined with vats in the treatment of multiple primary lung cancers (mplc).

patients will be first screened, and only after meeting all the selection criteria, not meeting any exclusion criteria, and signing the informed consent, could they be enrolled in the group to receive enb-guided ablation therapy combined with vats. the primary endpoint is objective response rate (orr). the secondary endpoints include progression-free survival (pfs), overall survival (os) and safety.

Eligibility criteria:
inclusion criteria: 1. age ≥ 18 years old. 2. the subject is diagnosed as multiple primary lung cancer via preoperative imaging/pathological examination. 3. thin-slice ct images show that the ablation lesion a is accessible/adjacent to bronchi and the size is ≤ 3 cm. 4. the subject with multiple primary lung cancers can be treated with enb-guided ablation therapy combined with vats according to multidisciplinary assessment. exclusion criteria: 1. the subject who cannot tolerate general anesthesia for their cardiopulmonary function, or there are other contraindications, such as uncorrectable coagulopathy. 2. the situation in which the investigators think that the subject is not suitable to participate in this study.

Keywords: electromagnetic navigation bronchoscopy (enb) video-assisted thoracic surgery (vats) multiple primary lung cancers (mplc) ablation therapy
angiotensin ii receptor blockers, steroids and radiotherapy in glioblastoma

Conditions: Newly-diagnosed Glioblastoma

Summary: to assess the efficacy of an angiotensin-ii inhibitor (losartan) to reduce peritumoral edema in newly diagnosed glioblastoma patients.

multicentre, randomized (1:1), double blinded trial:- arm a: standard of care (radiotherapy with concomitant temozolomide followed by monthly cures of temozolomide ) + losartan 50mg\*2/day until the halting for any reason - arm b: standard of care (radiotherapy with concomitant temozolomide followed by monthly cures of temozolomide + placebo 2/day until the halting for any reason.

Eligibility criteria:
inclusion criteria: * 18 years or older * histologically confirmed glioblastoma (grade 4 who) * patients eligible for radiotherapy and concomitant temozolomide * kps ≥ 50% * adequate hematologic, liver and renal functions exclusion criteria: * patients unable to undergo an mri with contrast * patients without any residual tumor left on the screening mri of both flair and contrast-enhanced lesions complete surgical resection) * any prior treatment of glioblastoma including any local therapy (immunotherapy, gliadel wafers, .....) during or after surgical resection * any on-going treatment for high blood pressure at time of inclusion, whatever the therapeutic class of drugs * systolic blood pressure \<110 mmhg. * relative or definite contra-indication to losartan: * pregnant or breast feeding women; women with an intact uterus (unless amenorrhoeic for the last 24 months) not using effective means of contraception * non-affiliation to the "sécurité sociale"

Keywords: glioblastoma angiotensin-ii inhibitors losartan steroids radiotherapy edema randomized trial